Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (February 2005)
45 slides from Curis's investor presentation, Feb 2, 2005
Slide 1: Corporate Presentation February 2, 2005
Regulating the Pathways of Health NASDAQ: CRIS Corporate Presentation February 2, 2005 ©2005 Curis Inc.
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Curis’ drug discovery and development programs. Such statements may contain the words “believes”, “expects”, “antici
Slide 3: Investment Highlights
Investment Highlights ¾ Diverse Portfolio of Promising Drug Candidates • Multiple programs with blockbuster potential • Pipeline of assets at various stages of development provide robust and growing portfolio ¾ Sustainable Business Model • Multiple partnerships with various deal structures to reduce
Slide 4: Presentation Outline
Presentation Outline Company Overview/Portfolio Partnerships and Products Patents/Financials/Summary 4 ©2005 Curis Inc.
Slide 5: Company Overview
Company Overview ¾ Curis is a therapeutic product development company with proprietary technology focused on regenerative signaling pathways ¾ Curis’ product development utilizes proteins or small molecules to activate or inhibit these signaling pathways ¾ Curis has developed several promising thera
Slide 6: Regenerative Signaling Pathways Control Many Key Regulatory Processes
Regenerative Signaling Pathways Control Many Key Regulatory Processes Recruitment Differentiation Proliferation Regeneration Repair Growth Stem Progenitor Specialized Cells Cells Cells 6 ©2005 Curis Inc.
Slide 7: Partnership / Collaboration Portfolio
Partnership / Collaboration Portfolio Therapeutic Area Partnership / Collaboration Cancer / Oncology Kidney Disease Neurological Disorders Hair Growth Regulation Cardiovascular Disease Motor Neuron Diseases 7 ©2005 Curis Inc.
Slide 8: Up Front Payments, Potential Milestones, and Potential Product Royalties
Up Front Payments, Potential Milestones, and Potential Product Royalties ¾ Up-Front Payments • Genentech ($8.5 M) • Ortho Biotech-J&J ($3.5 M) $15 Million • Wyeth Pharmaceuticals ($3 M) ¾ Potential Aggregate Milestones • Genentech (not disclosed) • Ortho Biotech-J&J (not disclosed) $500 Million • Wy
Slide 9: Basal Cell Carcinoma and Solid Tumor Cancers
Basal Cell Carcinoma and Solid Tumor Cancers (Hedgehog Antagonist Technologies) Partnered with 9 ©2005 Curis Inc.
Slide 10: Genentech Partnership
Genentech Partnership Established: June 2003 Deal structure: $8.5 million up-front payment, development milestones, product royalties, minimum two years R&D support, BCC co- development option Primary indications: Basal cell carcinoma (BCC) and solid tumors First IND filing: Q1 ‘05 for BCC Additiona
Slide 11: Cancers Associated with Abnormal Expression of the Hedgehog Pathway
Cancers Associated with Abnormal Expression of the Hedgehog (Hh) Pathway ¾ Mutation Associated • Basal Cell Carcinoma • Medulloblastoma ¾ Abnormal Expression Associated • Small Cell Lung Cancer • Pancreatic Carcinoma • Stomach Cancer • Esophageal Cancer • Prostate Cancer • Colorectal Cancer • Breast
Slide 12: Small Molecule Hedgehog Antagonists can Eliminate Basal Cell Carcinoma
Small Molecule Hedgehog Antagonists can Eliminate Basal Cell Carcinoma* Basal Cell Carcinoma Model Untreated Skin Cancer Model Skin Cancer Model Treated w/ Topical Hh Antagonist from Williams et al, 2003 *Curis has elected to co-develop 12 ©2005 Curis Inc.
Slide 13: Basal Cell Carcinoma (BCC) Curis Co-Development
Basal Cell Carcinoma (BCC) Curis Co-Development Co-development: Profit sharing structure commensurate with cost-sharing contributions (equal participation) Option exercise date: Announced February 1, 2005 Disease incidence: 800,000 to 1 million cases annually in the U.S.* Marketing advantage: Non-su
Slide 14: BCC – Hh Antagonist Pilot Human Clinical Study by Independent Investigators
BCC – Hh Antagonist Pilot Human Clinical Study by Independent Investigators Study goal: To assess the potential of a Hedgehog (Hh) pathway antagonist as a treatment for basal cell carcinoma (BCC) Hh antagonist: Cyclopamine Study design: Four patients with established BCCs, who were scheduled for exc
Slide 15: BCC – Hh Antagonist Pilot Human Clinical Study by Independent Investigators
BCC – Hh Antagonist Pilot Human Clinical Study by Independent Investigators Placebo Treated Day 2 Untreated Tumor Cyclopamine Treated Day 2 15 from Taş and Avcı, 2004 ©2005 Curis Inc.
Slide 16: BCC – Hh Antagonist Pilot Human Clinical Study by Independent Investigators
BCC – Hh Antagonist Pilot Human Clinical Study by Independent Investigators Study results: All cyclopamine-treated tumors regressed rapidly Histological analysis showed inhibition of tumor cell proliferation and induction of tumor cell apoptosis No adverse effects were noted on normal skin tissue Re
Slide 17: Cancers Associated with Abnormal Expression of the Hedgehog Pathway
Cancers Associated with Abnormal Expression of the Hedgehog (Hh) Pathway ¾ Mutation Associated • Basal Cell Carcinoma • Medulloblastoma ¾ Abnormal Expression Associated • Small Cell Lung Cancer • Pancreatic Carcinoma • Stomach Cancer • Esophageal Cancer • Prostate Cancer • Colorectal Cancer • Breast
Slide 18: Abnormal Hedgehog Expression Provides Growth Support for Certain Cancers
Abnormal Hedgehog Expression Provides Growth Support for Certain Cancers Certain Cancers Hedgehog Protein Adjacent Stromal Cells Angiogenesis Factors Growth Factors VEGF IGF-I Ang-1 BDNF Ang-2 NGF 18 ©2005 Curis Inc.
Slide 19: Curis Technologies Block the Hh Pathway
Curis Technologies Block the Hh Pathway Certain Cancers Small Hedgehog Antibodies Molecules Protein Adjacent Stromal Cells Angiogenesis Factors Growth Factors VEGF IGF-I Ang-1 BDNF Ang-2 NGF 19 ©2005 Curis Inc.
Slide 20: Genentech Partnership: Anticipated Milestones
Genentech Partnership: Anticipated Milestones First IND filing Q1 2005 for BCC Co-Development Selection of lead drug Curis estimates mid- as development candidate 2005 for other solid for other solid tumors tumors First IND filing Curis estimates for other solid tumors 2006 (triggers mile- stone pay
Slide 21: Kidney Disease and Associated Disorders
Kidney Disease and Associated Disorders (BMP-7 Protein Therapy) Partnered with a subsidiary of 21 ©2005 Curis Inc.
Slide 22: Ortho Biotech (J&J) Partnership
Ortho Biotech (J&J) Partnership Established: November 2002 Deal structure: $3.5 million up-front payment, development milestones including $30 million on NDA approval, product royalties Primary indications: Chronic kidney disease and disorders associated with end stage kidney disease 22 ©2005 Curis
Slide 23: The BMP Signaling Pathway is Required for Normal Kidney Development
The BMP Signaling Pathway is Required for Normal Kidney Development Normal BMP-7 Deficient from Dudley et al, 1995 23 ©2005 Curis Inc.
Slide 24: BMP-7 can Halt Disease Progression in Models of Kidney Disease
BMP-7 can Halt Disease Progression in Models of Kidney Disease Normal Injured Kidneys Kidney Untreated BMP-7 Treated 24 ©2005 Curis Inc.
Slide 25: BMP-7 Promotes Kidney Function and Prevents Skeletal Deterioration
BMP-7 Promotes Kidney Function and Prevents Skeletal Deterioration BMP-7 maintains BMP-7 kidney structure promotes and function skeletal mineralization BMP-7 prevents vascular calcification 25 ©2005 Curis Inc.
Slide 26: Ortho Biotech (J&J) Partnership
Ortho Biotech (J&J) Partnership Estimated IND filing: Curis estimates late 2005 - 2006 (milestone payment upon acceptance) Disease incidence: Approximately 423,000 patients have end-stage renal disease in U.S.* Marketing advantage: Presently no effective therapies for treating renal disease and asso
Slide 27: Neurological Disorders
Neurological Disorders (Hedgehog Pathway Agonists) Partnered with 27 ©2003 Curis ©2005 Curis Inc. Inc.
Slide 28: Wyeth Partnership
Wyeth Partnership Established: January 2004 Deal structure: $3 million up-front payment, development milestones of up to $170 million, product royalties, minimum two years R&D support Primary indications: Stroke and other neurological disorders 28 ©2005 Curis Inc.
Slide 29: Hedgehog Pathway is Activated in Response to Nerve Injury
Hedgehog (Hh) Pathway is Activated in Response to Nerve Injury BLUE staining Relative Level of Hedgehog mRNA denotes presence of Hedgehog 600 400 Day 0 Day 1 200 0 0 1 3 7 13 Time After Injury (days) 29 from internal Curis research ©2005 Curis Inc.
Slide 30: Treatment with Small Molecule Hh Agonist Reduces Infarct Size in a Model of Stroke
Treatment with Small Molecule Hh Agonist Reduces Infarct Size in a Model of Stroke Stroke Neuroprotection Model Infarct Area Vehicle Hh Agonist 30 from internal Curis research ©2005 Curis Inc.
Slide 31: Wyeth Partnership
Wyeth Partnership Estimated IND filing: Curis estimates late 2006 (will trigger milestone payment) Disease incidence: Approximately 700,000 patients suffer a stroke each year in U.S.* Marketing advantage: Presently no effective therapies for treating stroke * American Heart Association, Heart Diseas
Slide 32: Hair Growth Regulation
Hair Growth Regulation (Hedgehog Agonist Technologies) Development by 32 ©2005 Curis Inc.
Slide 33: Hedgehog Pathway Regulates Initiation and Maintenance of Hair Growth
Hedgehog Pathway Regulates Initiation and Maintenance of Hair Growth Hair Growth Model Day 4 Day 4 Day 7 Stimulated Replicating New Hair Hair Hair Follicle Shaft Follicles Cells Growing 33 from internal Curis research ©2005 Curis Inc.
Slide 34: Small Molecule Hedgehog Agonist Promotes Hair Growth in a Preclinical Model
Small Molecule Hedgehog Agonist Promotes Hair Growth in a Preclinical Model Vehicle Treated Agonist Treated One dose, topical application, day 13 after treatment 34 from internal Curis research ©2005 Curis Inc.
Slide 35: Hair Growth Regulation Program
Hair Growth Regulation Program ¾Primary indications • Male pattern baldness • Female hair loss ¾Earliest IND filing • Curis estimates 2006 35 ©2005 Curis Inc.
Slide 36: Cardiovascular Disease
Cardiovascular Disease (Hedgehog Agonist Technologies) Development by 36 ©2005 Curis Inc.
Slide 37: The Hedgehog Pathway Promotes Development of New Blood Vessels
The Hedgehog Pathway Promotes Development of New Blood Vessels Pellet containing Hedgehog protein Day 0 Day 6 37 from Pola et al, 2001 ©2005 Curis Inc.
Slide 38: Hedgehog Treatment Reduces Myocardial Fibrosis and Promotes Neovascularization
Hedgehog Treatment Reduces Myocardial Fibrosis and Promotes Neovascularization Acute Myocardial Infarction Model Fibrosis Area (%) Capillary Density (cap./mm2) 35 700 P<0.05 30 600 * * 25 500 P<0.01 20 400 15 * * 300 10 200 5 100 0 0 PBS LacZ 30 300 600 PBS LacZ 30 300 600 µg Hh DNA µg Hh DNA 38 fro
Slide 39: Curis Cardiovascular Program
Curis Cardiovascular Program ¾Primary indications • Acute Myocardial Infarction • Peripheral Vascular Disease 39 ©2005 Curis Inc.
Slide 40: Spinal Muscular Atrophy
Spinal Muscular Atrophy (and other motor neuron diseases) Development by 40 ©2005 Curis Inc.
Slide 41: Spinal Muscular Atrophy Foundation Grant
Spinal Muscular Atrophy Foundation Grant Established: September 2004 Deal structure: $5.4 million over three years to identify and develop Curis-owned therapeutic compounds using proprietary motor neuron assays Primary indications: Spinal muscular atrophy and other motor neuron disorders Deal signif
Slide 42: Strong Intellectual Property Position
Strong Intellectual Property Position ¾ Approximately 164 US patents issued or allowed and 121 pending in US; 277 foreign patents issued or allowed and 368 foreign patents pending ¾ Compositions of matter covering signaling proteins, receptors, antibodies, small molecule agonists and antagonists, an
Slide 43: Financial Data
Financial Data December 31, 2004 (amounts in 000’s except per share data) Cash, cash equivalents, investments $ 52,100 Convertible debt $ 5,700 (1) Other debt $ 1,100 Shareholders’ equity $ 48,900 Basic shares outstanding 47,500 Fully diluted shares outstanding 59,000 2004 loss per share (fully dilu
Slide 44: Summary: Balanced Business Model
Summary: Balanced Business Model ¾ Diverse portfolio of attractive drug candidates • Three programs partnered with world class pharma • Risk diversification with substantial revenue potential ¾ Addresses blockbuster indications • Skin cancer (co-development option with Genentech) • Other oncology ap
Slide 45: Corporate Presentation February 2, 2005
Regulating the Pathways of Health NASDAQ: CRIS Corporate Presentation February 2, 2005 ©2005 Curis Inc.